

# STELLAR<sup>303</sup>

## Metastatic Colon or Rectal Cancer Clinical Trial Discussion Guide

This guide can help you talk with your doctor about joining a clinical trial. The first step is to ask your doctor about whether you may be eligible to take part in the study.

**STELLAR-303** is a clinical trial studying a combination of study drugs, XL092 and atezolizumab, for colon or rectal cancer that has spread to other parts of the body (metastatic cancer). Both you and your doctor can find additional information about this clinical trial on [clinicaltrials.gov](https://clinicaltrials.gov) by searching for **NCT05425940**.

### 1 Questions about your cancer and prior medicines

- STELLAR-303 is studying a potential new treatment for metastatic colon or rectal cancer. Is this the type of cancer I have?
- STELLAR-303 is only an option for people who have already received prior treatments for metastatic colon or rectal cancer. Did my cancer continue to grow or spread after my prior treatments? Can we review all the medicines I have taken so far to understand if the trial may be an option for me?

NOTES: \_\_\_\_\_

### 2 Questions about taking part in a clinical trial

- What are my treatment options? Is a clinical trial an option for me?
- What are the potential risks and benefits if I join?
- How might being in the clinical trial affect my daily life?
- How long will participation in the clinical trial last, and can I quit the clinical trial once I start?
- Will I be able to get other treatment if the medicines I'm given during the clinical trial don't work?
- Will I find out the results of the clinical trial?

NOTES: \_\_\_\_\_

### 3 Questions about financial costs

- Will it cost me anything to be in the study?
- If there are costs, will they be covered by my health insurance?

NOTES: \_\_\_\_\_

If your doctor is not taking part in STELLAR-303 research, you may need to discuss some questions with a doctor who is.

For more information, please call Exelixis Medical Information at **1-888-393-5494** (toll-free) or **1-303-389-1847**, or email [medinfo@exelixis.com](mailto:medinfo@exelixis.com).

THE COMBINATION OF XL092 AND ATEZOLIZUMAB HAS NOT BEEN APPROVED BY THE FDA. THE SAFETY AND EFFECTIVENESS OF THIS STUDY TREATMENT HAVE NOT BEEN ESTABLISHED AND ARE BEING STUDIED AS PART OF THIS CLINICAL TRIAL.